|Bid||5.30 x 3000|
|Ask||5.28 x 1300|
|Day's Range||5.20 - 5.62|
|52 Week Range||3.14 - 9.53|
|Beta (5Y Monthly)||1.03|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 14, 2022 - Feb 18, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||10.00|
The mean of analysts' price targets for Immunovant, Inc. (IMVT) points to a 142.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Immunovant's (IMVT) earnings beat estimates in the fiscal first quarter ended on Jun 30, 2022. The company is evaluating batoclimab in a pivotal study for treating myasthenia gravis.
NEW YORK, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today reported recent company updates and financial results for its fiscal first quarter ended June 30, 2022. Recent Updates and Anticipated Milestones: Immunovant initiated a pivotal clinical trial of batoclimab in Myasthenia Gravis in June 2022. Top-line data from the trial are expected in the second half o